The LEADER study found that nearly 83% of early Alzheimer's patients remained stable or improved while on LEQEMBI treatment for an average of 17 months, consistent across demographics and genetic profiles. LEQEMBI targets amyloid beta to slow cognitive decline, and continuous treatment may help maintain early disease stages longer. Safety data aligned with FDA guidelines, with manageable side effects. This real-world evidence supports LEQEMBI's long-term benefits beyond clinical trials.
Biogen announced positive Phase 2 results for diranersen, an antisense therapy targeting tau protein in early Alzheimer's disease. The study showed meaningful clinical benefits, including slowing cognitive decline by up to 50% on some measures, and r...
The FDA has approved LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating treatment of early Alzheimer's disease, allowing at-home dosing. This new form offers a convenient alternative to intravenous infusions, providing flexibility for...
Biogen's stock received an upgrade as investors anticipate the company's upcoming announcement of detailed data from its Phase 2 study on an experimental Alzheimer's drug. This data release is significant because it could impact the future of Alzheim...
Eisai and Biogen presented data at AAIC 2026 showing that LEQEMBI's subcutaneous autoinjector delivers similar efficacy and safety to intravenous administration for early Alzheimer's disease. The once-weekly 500 mg subcutaneous dose achieves comparab...
